Principal Financial Group Inc. lifted its stake in shares of Albany Molecular Research, Inc. (NASDAQ:AMRI) by 0.2% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 171,060 shares of the biotechnology company’s stock after purchasing an additional 374 shares during the quarter. Principal Financial Group Inc. owned about 0.41% of Albany Molecular Research worth $3,712,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the company. Arizona State Retirement System grew its stake in shares of Albany Molecular Research by 0.9% during the 1st quarter. Arizona State Retirement System now owns 11,586 shares of the biotechnology company’s stock worth $163,000 after purchasing an additional 100 shares during the period. Texas Permanent School Fund grew its stake in shares of Albany Molecular Research by 0.9% during the 2nd quarter. Texas Permanent School Fund now owns 16,299 shares of the biotechnology company’s stock worth $354,000 after purchasing an additional 151 shares during the period. Teachers Advisors LLC grew its stake in shares of Albany Molecular Research by 0.5% during the 4th quarter. Teachers Advisors LLC now owns 41,916 shares of the biotechnology company’s stock worth $786,000 after purchasing an additional 198 shares during the period. Sii Investments Inc. WI grew its stake in shares of Albany Molecular Research by 2.2% during the 1st quarter. Sii Investments Inc. WI now owns 11,460 shares of the biotechnology company’s stock worth $161,000 after purchasing an additional 250 shares during the period. Finally, Municipal Employees Retirement System of Michigan grew its stake in shares of Albany Molecular Research by 5.8% during the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 5,260 shares of the biotechnology company’s stock worth $114,000 after purchasing an additional 290 shares during the period. 72.10% of the stock is currently owned by institutional investors and hedge funds.

A number of research firms have recently weighed in on AMRI. First Analysis cut shares of Albany Molecular Research from an “overweight” rating to an “equal weight” rating in a research note on Monday, June 12th. J P Morgan Chase & Co cut shares of Albany Molecular Research from an “overweight” rating to a “neutral” rating in a research note on Thursday, June 8th. Finally, BidaskClub raised shares of Albany Molecular Research from a “sell” rating to a “hold” rating in a research note on Friday, August 11th. Five equities research analysts have rated the stock with a hold rating, The stock currently has an average rating of “Hold” and an average price target of $18.00.

COPYRIGHT VIOLATION NOTICE: “Albany Molecular Research, Inc. (AMRI) Stake Boosted by Principal Financial Group Inc.” was first published by Watch List News and is owned by of Watch List News. If you are reading this news story on another domain, it was copied illegally and republished in violation of US and international copyright law. The legal version of this news story can be accessed at https://www.watchlistnews.com/albany-molecular-research-inc-amri-stake-boosted-by-principal-financial-group-inc/1611727.html.

About Albany Molecular Research

Albany Molecular Research, Inc is a contract research and manufacturing company. The Company operates through Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), Drug Product (DP) and Fine Chemicals (FC) segments. The DDS segment includes activities, such as drug lead discovery, optimization, drug development and small scale commercial manufacturing.

Want to see what other hedge funds are holding AMRI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Albany Molecular Research, Inc. (NASDAQ:AMRI).

Institutional Ownership by Quarter for Albany Molecular Research (NASDAQ:AMRI)

Receive News & Ratings for Albany Molecular Research Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albany Molecular Research Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.